Dr. Martinez joined BioGX in 2015. Dr. Martinez is responsible for Business Development and Scientific Affairs, expanding our portfolio of IVD products, managing the global technical support efforts of all molecular diagnostic products, and manages a team of scientists responsible for product and technology innovation in conjunction with existing corporate partnerships. Dr. Martinez has over 20 years of experience in molecular biology. Prior to joining BioGX, Dr. Martinez held research positions focusing on cancer cell biology at Albany Medical College, microbial community dynamics at The Georgia Institute of Technology and microbial physiology at The University of Alabama. Dr. Martinez holds a BA in Biology from Boston University and a Ph.D. in Microbiology from The Georgia Institute of Technology.
Mr. Green joined BioGX as a Controller in 2020. He has 30+ years of leadership experience in accounting across diverse industries, including healthcare, water utility management, waste management, mineral extraction, and cash handling. At BioGX, Mr. Green is responsible for managing finance and purchasing departments. He has a BS degree in Accounting from The University of Alabama, and he is a Certified Public Accountant (inactive).
Dr. Shazi Iqbal is a Co-Founder of BioGX and served as its CEO from 2011 to June 2024. Now, as a Venture Partner, he leads M&A and strategic investment opportunities to enable innovation partnerships. Dr. Iqbal has over 25+ years of experience in building healthcare startups into profitable growth companies. He holds a Ph.D. in Biology (Neuroscience), two M.S. degrees in Biochemistry & Biotechnology, and several patents and publications.
Targets |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bacteria | Viruses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Dr. Shahin Iqbal is the President and Chief Operating Officer at BioGX. He has over 25 years of experience in clinical molecular diagnostics. Before joining BioGX, Dr. Iqbal led the Abbott Diagnostics Global Service & Support specifically for informatics, core lab automation, immunoassay and clinical chemistry systems. He was also responsible for design and development of FISH automation systems at Abbott Molecular. He is the recipient of the President awards and multiple service & innovation awards at Abbott. Dr. Iqbal holds multiple patents on optical sensors, automation systems development, RFID applications and robotics for system dispensing. Prior to joining Abbott, Dr. Iqbal was Head of operations, quality & regulatory, systems development and manufacturing of IHC systems at BioGenex in California. Dr. Iqbal has an MBA and Ph.D as well as a Masters in Electrical Engineering degree from the University of Texas in San Antonio.
Mr. Blackstone joined BioGX in 2007. He has served at BioGX in various senior R&D and quality management roles prior to his current position as VP of Research & Development. Mr. Blackstone has designed and directed the development of over 100 multiplex real time PCR products in the fields of food safety, water quality, pharma QC, and clinical diagnostics. Mr. Blackstone previously served for eight years at the US Food and Drug Administration and as a Commissioned Research Officer in the US Public Health Service Commissioned Corps where he achieved the rank of Lieutenant Commander. George Blackstone received his Master of Science degree from Louisiana State University.
Mr. Hughes joined BioGX in 2015. Prior to joining BioGX, Mr. Hughes led efforts for a diverse range of companies with the development and implementation of certified quality management systems ranging from data storage devices with SONY Corporation, security & detention devices with Norment Security Group, textile manufacturing with Twitchell Corporation, combat vehicle manufacturing with General Dynamics, and therapeutic medical devices with Steris Corporation. Christopher has a BSE from Auburn University and an MBA from Troy State University.
If you are contacting us because you have received a phone call offering genetic testing services, with the caller requesting personal health information and personal identification numbers (such as Medicare Card numbers), please know that we are NOT responsible for such calls.
We, BioGX, Inc., (registered trademark “BioGX”) with offices in Birmingham, AL, Dallas, TX, and Amsterdam, The Netherlands, are a diagnostic test manufacturer and not a testing laboratory, and we are not in any way affiliated with such callers. We do not know who is making these calls.
UNDER NO CIRCUMSTANCES BIOGX WOULD EVER CONTACT INDIVIDUALS TO OFFER GENETIC TESTING SERVICES OR REQUEST PERSONAL INFORMATION OF ANY KIND.
This Fact Sheet informs you of the significant known and potential risks and benefits of the use of the BioGX Xfree™ COVID-19 Direct RT-PCR.
The BioGX Xfree™ COVID-19 Direct RT-PCR is validated for use with respiratory specimens collected from individuals suspected of COVID-19 by their healthcare provider.
QuantStudio™ 5 Direct Sample Run File
QuantStudio™ 5 Direct Sample PDF
CFX96 Touch™ Direct Sample Run File 1
CFX96 Touch™ Direct Sample Run File 2
CFX96 Touch™ Direct Sample PDF
Dr. Vickery founded BioGX in 2007 and served as President and CEO until 2011. Prior to founding BioGX, Dr. Vickery worked in sales and as a technical consultant at Cepheid. Prior to Cepheid, Dr. Vickery worked at the FDA as a University of Maryland JIFSAN postdoctoral fellow at the University of Maryland, and later served as the Lead for Molecular Methods Development at the U.S. FDA Gulf Coast Seafood Laboratory. He holds multiple patents in biotechnology, has authored or co-authored many publications, and has extensive experience in gene expression analysis, and in the design and development of rapid multiplex molecular tests for microbial and viral detection. Dr. Vickery holds a B.S. degree in Physics and both M.S. and Ph.D. degrees in Biology (molecular biology and molecular genetics focus – both prokaryotic and eukaryotic). Prior to entering graduate school, Dr. Vickery worked as an executive in the lowbed trailer industry for almost 10 years, pioneering the sale of American made heavy equipment transport trailers into China (ROC) and Japan during his tenure in the industry, and resupplying the oilfields of Kuwait with specialized trailers after the Gulf War.
BioGX Expands PCR Test Menu at State Departments of Health
BIRMINGHAM, AL / January 11, 2024 / BioGX, a leading global provider of easy molecular diagnostic solutions, is pleased to announce the test menu expansion support to Departments of Health (DoH) with the addition of its Candida auris assay. BioGX currently services 6 DoH agencies with expansion to 10 agencies expected in Q1 2024. “We are […]
Microbix & BioGX Collaborate on real-time PCR Assays & Controls
Quality Controls for Respiratory Viral, Pharyngitis, and Genital Ulcer Disease Panels Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces a collaboration with BioGX, Inc. (“BioGX”), a global provider of easy molecular diagnostic solutions. The companies are collaborating to make Microbix’s Quality Assessment Products (“QAPs™”) available to BioGX […]
BioGX Expands Xfree Respiratory PCR With COVID-19/Flu A/Flu B Multiplex, Group A Streptococcus, Mycoplasma Pneumoniae
BIRMINGHAM, AL / ACCESSWIRE / September 7, 2023 / BioGX, a global provider of molecular diagnostic solutions, announces the availability of three new Xfree™ Direct-Sample-to-Answer PCR multiplexes for the detection of Group A Streptococcus, Mycoplasma pneumoniae and Flu A, Flu B, COVID-19 N1/RdRp. Xfree Flu A, Flu B, COVID-19 and Group A Streptococcus were previously CE-IVD marked […]
BioGX Candida Auris PCR Assay Global Adoption Accelerates
BIRMINGHAM, Ala., July 23, 2023 (Newswire.com) – BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities. A complete PCR mix is provided in a single […]
BioGX Candida auris PCR Assay Adoption Accelerates
BIRMINGHAM, Ala., March 23, 2023 (Newswire.com) – BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities. A complete PCR mix is provided in a single […]
BioGX Ships First Batch of pixl™ Real-Time PCR Platform to US Laboratories
BIRMINGHAM, Ala., February 28, 2023 (Newswire.com) – BioGX, a global provider of easy molecular diagnostic solutions since 2007, has announced fulfillment of multiple initial orders for its portable pixl™ real-time PCR platform to customers across the U.S., with immediate plans to scale production to meet market demand. “We’re very impressed with the response to the launch […]
BioGX Launches ‘pixl™’ Portable qPCR Platform Ex-US With Expanded Test Menu for Infectious Diseases
BIRMINGHAM, Ala., December 8, 2022 (Newswire.com) – BioGX, a global provider of easy molecular diagnostic solutions since 2007, announced the Ex-US commercial release of its portable pixl™ qPCR real-time PCR platform for use with BioGX CE-IVD marked assays, enabling global access and complementing the recent US FDA EUA expanded use of Xfree™ COVID-19 Direct RT-PCR on […]
BioGX Expands FDA EUA with pixl™ Portable qPCR System for its Direct-Sample COVID-19 Assay
Birmingham, Alabama, Nov 10, 2022 – BioGX, a global provider of easy molecular diagnostic solutions since 2007, announced that the US FDA has updated their original (June 29, 2021) Direct Sample XfreeTM COVID-19 Emergency Use Authorization to increase the shelf-life of the assay reagent to 15 months and expand its use to additional real-time PCR […]
BioGX Announces Availability of Xfree PCR Reagents for Monkeypox
BIRMINGHAM, Ala.–(BUSINESS WIRE)–To address the growing need for simplified, rapid testing for Monkeypox, BioGX, a global provider of easy molecular diagnostic solutions, announced availability of Xfree PCR reagents for Sample-to-Answer Direct Sample PCR on multiple real-time PCR platforms including BioGX’s rapid “pixl” platform. Dr. Suzane Silbert, Director, Esoteric Testing/R&D and Microbiology Laboratories at Tampa General […]
BioGX Launches CE-IVD Marked Multi-gene COVID-19 Point-of-Care Test at AACC
CHICAGO–(BUSINESS WIRE)–BioGX, a global provider of easy molecular diagnostic solutions, announced the launch of a point-of-care (POC) CE-Marked, three gene multiplex COVID-19 test on its pixl platform. The test utilizes BioGX’s highly successful Xfree direct sample testing chemistry that is included in its US FDA emergency use authorized Xfree COVID-19 Direct RT-PCR test. This new […]